Title : Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.

Pub. Date : 2018

PMID : 30568660






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We show that a frequency of < 9.4% of SIRPalpha/beta-expressing memory B cells predicts patients that will develop ADA, and consequentially fail to respond to treatment, with a receiver operating characteristic (ROC) area under the curve (AUC) score of 0.92. N-(2-acetamido)iminodiacetic acid signal regulatory protein alpha Homo sapiens
2 Thus, measuring the frequency of SIRPalpha/beta-expressing memory B cells in patients prior to adalimumab treatment may be clinically useful to identify a subgroup of active RA subjects who are going to develop an ADA response and not gain substantial clinical benefit from this treatment. N-(2-acetamido)iminodiacetic acid signal regulatory protein alpha Homo sapiens